RadarScreener › CVKD

CVKD

Cadrenal Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations · EDGAR filings (CIK 1937993) · 8 signals · 1 setups · updated Aug 16, 2026

What the filings say Pressure ▼

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.

Radar 85 (high attention) · dilution pressure elevated · listing risk elevated · governance risk high · runway 2.7 mo · strongest signal: Departure cluster (Jul 17, 2026)

What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

85Radar · attention score (0–100)
62Dilution pressure · financing + balance sheet
43Listing risk · exchange standards
76Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Forced-raise setup Pressure ▼ strength 0.85

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language, runway < 6 months) coexists with live selling machinery (shelf effective, offering (424b)). Base case is a discounted raise; the question is when, not if.

Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Going-concern languageRunway < 6 monthsShelf effectiveOffering (424B)

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on CVKD
Alerts
One email the morning CVKD files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for CVKD back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 985 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$2.4Mcash + short-term investments as of Jun 30, 2026
2.7 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$4.1Mstockholders' equity as of Jun 30, 2026
$24.9Mpublic float (10-K cover)
3.6Mshares outstanding as of Aug 13, 2026 · was 2.9M May 6, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Aug 13, 2026 Going-concern language “going concern periodic” language in 10-Q (10-Q) filed 2026-08-13 filing 29
Aug 3, 2026 Reverse split “reverse split” language in DEF 14A (DEF 14A) filed 2026-08-03 filing 27
Jul 23, 2026 Reverse split “reverse split” language in PRE 14A (PRE 14A) filed 2026-07-23 filing 27
Jul 20, 2026 Offering (424B) 424B3 prospectus supplement 2026-07-20; 7 prior 424B filings in 12m filing 28
Jul 20, 2026 Shelf effective EFFECT notice 2026-07-20 filing 21
Jul 17, 2026 Departure cluster 4 Item 5.02 8-Ks in 90 days (latest 2026-07-17) filing 64
Jul 17, 2026· Officer/director change 8-K Item 5.02 filed 2026-07-17 (accepted 16:15 ET) filing 24
Jun 30, 2026 Runway < 6 months ~2.7 months runway: liquidity $2,388,135 as of 2026-06-30, burn $10,616,169/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing 44

Other forced raise setups

VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans